Trial Profile
A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Aphthous stomatitis
- Focus Therapeutic Use
- 21 Mar 2022 Phase amended from early phase to phase IV.
- 21 Mar 2022 Status changed from active, no longer recruiting to completed.
- 29 Sep 2021 Planned End Date changed from 1 Aug 2021 to 1 Feb 2022.